169 related articles for article (PubMed ID: 2386542)
1. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.
Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL
Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
3. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.
Lakaschus G; Löffler M
Biochem Pharmacol; 1992 Mar; 43(5):1025-30. PubMed ID: 1313236
[TBL] [Abstract][Full Text] [Related]
4. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.
Chen SF; Ruben RL; Dexter DL
Cancer Res; 1986 Oct; 46(10):5014-9. PubMed ID: 3019518
[TBL] [Abstract][Full Text] [Related]
7. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Knecht W; Henseling J; Löffler M
Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
[TBL] [Abstract][Full Text] [Related]
9. Anti-arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis.
Kobayashi K; Nakashima A; Nagata H; Nakajima H; Yamaguchi K; Sato S; Miki I
Inflamm Res; 2001 Jan; 50(1):24-31. PubMed ID: 11235018
[TBL] [Abstract][Full Text] [Related]
10. Histidine to alanine mutants of human dihydroorotate dehydrogenase. Identification of a brequinar-resistant mutant enzyme.
Davis JP; Copeland RA
Biochem Pharmacol; 1997 Aug; 54(4):459-65. PubMed ID: 9313772
[TBL] [Abstract][Full Text] [Related]
11. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).
Peters GJ; Sharma SL; Laurensse E; Pinedo HM
Invest New Drugs; 1987; 5(3):235-44. PubMed ID: 2822596
[TBL] [Abstract][Full Text] [Related]
13. Dihydroorotate dehydrogenase inhibitors: quantitative structure-activity relationship analysis.
Ren S; Wu SK; Lien EJ
Pharm Res; 1998 Feb; 15(2):286-95. PubMed ID: 9523317
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Cleaveland ES; Zaharevitz DW; Kelley JA; Paull K; Cooney DA; Ford H
Biochem Biophys Res Commun; 1996 Jun; 223(3):654-9. PubMed ID: 8687451
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria.
Jöckel J; Wendt B; Löffler M
Biochem Pharmacol; 1998 Oct; 56(8):1053-60. PubMed ID: 9776318
[TBL] [Abstract][Full Text] [Related]
16. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Peters GJ; Schwartsmann G; Nadal JC; Laurensse EJ; van Groeningen CJ; van der Vijgh WJ; Pinedo HM
Cancer Res; 1990 Aug; 50(15):4644-9. PubMed ID: 2164443
[TBL] [Abstract][Full Text] [Related]
17. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
18. The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium.
de Kant E; Pinedo HM; Laurensse E; Peters GJ
Cancer Lett; 1989 Jul; 46(2):123-7. PubMed ID: 2546667
[TBL] [Abstract][Full Text] [Related]
19. The relationship between dihydroorotic acid dehydrogenase and in vitro and in vivo cytostatic effects of brequinar sodium (DUP-785; NSC 368390).
Peters GJ; Laurensse E; de Kant E; Nadal JC; Pinedo HM
Adv Exp Med Biol; 1989; 253B():375-82. PubMed ID: 2558540
[No Abstract] [Full Text] [Related]
20. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]